Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:28:09 EDT Sun 05 May 2024
Enter Symbol
or Name
USA
CA



News for U:RYTM from 2023-05-04 to 2024-05-03 - 43 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-29 18:30U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
2024-04-24 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
2024-04-16 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces New Employment Inducement Grants
2024-04-01 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
2024-03-25 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
2024-03-11 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces New Employment Inducement Grants
2024-03-06 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
2024-02-22 07:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
2024-02-22 07:00U:RYTMNews ReleaseRhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results ‚  and Business Update
2024-02-08 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces New Employment Inducement Grants
2024-02-07 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE ‚ ® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
2024-01-31 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
2024-01-12 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces New Employment Inducement Grants
2024-01-04 07:00U:RYTMNews ReleaseRhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640
2024-01-04 06:58U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates
2023-12-15 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces New Employment Inducement Grants
2023-12-13 07:00U:RYTMNews ReleaseRhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023
2023-12-06 07:00U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event
2023-11-13 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces New Employment Inducement Grants
2023-11-07 07:00U:RYTMNews ReleaseRhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results ‚  and Business Update
2023-11-02 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE ‚ ® (setmelanotide)
2023-10-25 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
2023-10-17 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek ‚ ® 2023
2023-10-13 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces New Employment Inducement Grants
2023-10-10 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society ¢ € ™s Annual Meeting at ObesityWeek ‚ ®
2023-09-22 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals Presents New Data at ESPE 2023
2023-09-19 08:01U:RYTMNews ReleaseRhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity
2023-09-08 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces New Employment Inducement Grants
2023-09-08 07:59U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Update to September Conference Participation
2023-09-06 07:59U:RYTMNews ReleaseRhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome
2023-08-28 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals to Present at Investor Conferences in September
2023-08-07 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France
2023-08-04 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces New Employment Inducement Grants
2023-08-01 07:00U:RYTMNews ReleaseRhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update
2023-07-19 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome
2023-07-17 06:00U:RYTMNews ReleaseRhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
2023-07-13 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces New Employment Inducement Grants
2023-06-17 14:01U:RYTMNews ReleaseRhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023
2023-06-07 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
2023-06-06 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces New Employment Inducement Grants
2023-05-22 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE ‚ ® (setmelanotide) to Patients in Gulf Cooperation Council Countries
2023-05-08 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE ‚ ® Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR Deficiency
2023-05-05 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces New Employment Inducement Grants